
Biotech firm Otonomy, listed in the US, has scored its first top-line results from clinical studies of the candidate OTO-413, a potential hearing loss treatment, the company reports in a press release.
In a phase IIa trial that included 30 participants with hearing loss, 20 people received an injection delivering the drug into the inner ear, while the remaining patients received a placebo. Multiple speech-in-noise (SiN) tests were conducted with the participants on day 57 and 85, which included a words-in-noise test where subjects have to distinguish words from background noise, a real-life challenge for those with hearing loss, Otonomy says.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app